Imaging of Atherosclerosis With 68Ga-MSA
- Conditions
- AtherosclerosisNoninvasive Imaging of Atherosclerosis
- Registration Number
- NCT01889693
- Lead Sponsor
- Korea University
- Brief Summary
Despite of intensive efforts, no specific ath¬erosclerosis-targeting agent labeled with positron emitter is not yet available. Fortunately, some scientists made the major advance in the field of clinical atherosclerosis molecular imaging by the metabolic PET reporter agent 18F(fluorine-18)-FDG(Fludeoxyglucose) applied to noninvasively image plaque macrophages in carotid arteries. However, coronary and cerebral arterial segments remain uninterpretable due to metabolic property of 18F-FDG. Applying the character of the terminal mannose residues of MSA binding with the mannose receptors of macrophages in atherosclerosis, we investigate whether 68Ga-MSA can be a novel agent for non-invasive molecular imaging of atherosclerotic lesion in PET.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
- acute coronary syndrome(acute myocardial infarction, unstable angina)
- chronic stable angina
- control without coronary artery disease
- pregnancy, allergy to albumin, chronic inflammatory disease
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method comparison of SUV(standard uptake unit) at atherosclerotic plaque of aorta and carotid arteries among 3 groups 1 day at the time of PET(positron emission tomogram) imaging
- Secondary Outcome Measures
Name Time Method side effect of PET imaging with 68Ga-MSA with 7 days after PET imaging any side effects including changes of biochemical values and vital signs
Trial Locations
- Locations (1)
Korea University Guro Hospital
🇰🇷Seoul, Korea, Republic of
Korea University Guro Hospital🇰🇷Seoul, Korea, Republic of